60 Degrees Pharmaceuticals, Inc. (SXTP) stock
SXTPNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as SXTPW
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 8/3060% below fair value
$0.54+0.00 (+0.71%)
Close on Nov 18, 2026Market cap $1.89MP/E –Yield –
60 Degrees Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
60 Degrees Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $2.33M, up 8.0% year over year. For fiscal 2025 it was $2.11M, down 57.8% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.11M | -57.8% |
| FY2024 | Dec 31, 2024 | $4.99M | +620.8% |
| FY2023 | Dec 31, 2023 | $691.77K | +31.6% |
| FY2022 | Dec 31, 2022 | $525.56K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $598.65K | +158.1% |
| Q1 FY2026 | Mar 31, 2026 | $281.46K | -24.1% |
| Q4 FY2025 | Dec 31, 2025 | $638.87K | +4.1% |
| Q3 FY2025 | Sep 30, 2025 | $809.78K | -13.9% |
| Q2 FY2025 | Jun 30, 2025 | $231.91K | -92.5% |
| Q1 FY2025 | Mar 31, 2025 | $370.81K | +10.0% |
| Q4 FY2024 | Dec 31, 2024 | $613.96K | +512.7% |
| Q3 FY2024 | Sep 30, 2024 | $940.06K | +256.5% |
| Q2 FY2024 | Jun 30, 2024 | $3.10M | +1418.3% |
| Q1 FY2024 | Mar 31, 2024 | $337.18K | +171.9% |
| Q4 FY2023 | Dec 31, 2023 | $100.20K | -50.8% |
| Q3 FY2023 | Sep 30, 2023 | $263.70K | +853.5% |
| Q2 FY2023 | Jun 30, 2023 | $203.87K | -11.9% |
| Q1 FY2023 | Mar 31, 2023 | $123.99K | – |
| Q4 FY2022 | Dec 31, 2022 | $203.46K | – |
| Q3 FY2022 | Sep 30, 2022 | $27.66K | – |
| Q2 FY2022 | Jun 30, 2022 | $231.39K | – |
See a number that looks wrong?